Purple Biotech Advances Oncology Drugs with New Funding

Purple Biotech (PPBT) has released an update.

Purple Biotech, listed on NASDAQ/TASE as PPBT, is advancing its clinical-stage oncology drugs, CM24 and NT219, aimed at treating cancers with high unmet medical needs. With a recent capital raise of $4 million, the company is poised to achieve its next clinical milestones and maintain operations through the first half of 2026. Investors may find potential growth in Purple Biotech’s pioneering therapies and robust pipeline designed to tackle significant challenges in the cancer treatment landscape.

For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.